RxDoctor Payments Data

Amanda Keith

Family · Danville, VANPI 1689034514

Payments from drug & device makers

$3,117in general payments, 2019–2025

Across 171 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$677
  • Novo Nordisk$479
  • Pfizer$202
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$190
  • Lilly USA, LLC$147
  • Abbott$141
  • plus $1K from 30 others

What the payments were for

  • Food & beverage$3,117100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,117 in reported general payments places this provider in the 85th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$30,194
Medicare patients
132
Services billed
570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$110,585
TrulicityDulaglutide59$64,616
MounjaroTirzepatide50$57,081
EliquisApixaban25$39,242
VraylarCariprazine Hcl25$33,877
JanuviaSitagliptin Phosphate23$23,330
RybelsusSemaglutide17$22,253
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$13,540
LinzessLinaclotide18$13,517
Combivent RespimatIpratropium/Albuterol Sulfate16$10,209
Spiriva HandihalerTiotropium Bromide17$9,977
MyrbetriqMirabegron11$8,562
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$5,788
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$5,449
Albuterol Sulfate HfaAlbuterol Sulfate152$4,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$479$132,837109 claims
Lilly USA, LLCTrulicity, Mounjaro$147$121,697109 claims
AbbVieVraylar, Linzess, Synthroid$677$48,95654 claims
PfizerEliquis$202$39,24225 claims
MerckJanuvia$49$23,33023 claims
Astellas Pharma US IncMyrbetriq$60$8,56211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,332 family providers in Virginia.

Other family in Danville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →